Association of negative symptoms with cognitive impairment in Chinese Han patients with chronic schizophrenia

References

• Bagney A, Dompablo M, Santabárbara J, Moreno-Ortega M, Lobo A, Jimenez-Arriero M-A, Palomo T, Rodriguez-Jimenez R. 2015. Are negative symptoms really related to cognition in schizophrenia? Psychiatry Res. 230(2):377–382.
   PubMed Web of Science ®Google Scholar
• Ballesteros A, Sánchez-Torres AM, López-Ilundain JM, Cabrera B, Lobo A, González-Pinto AM, Díaz-Caneja C, Corripio I, Vieta E, de la Serna E, et al. 2018. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? Psychol Med. 48(13):2247–2256.
   PubMed Web of Science ®Google Scholar
• Bartholomeusz CF, Allott K. 2012. Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence. Schizophr Res Treatment. 2012:815315–815315.
   PubMedGoogle Scholar
• Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. 2018. Relationship between effortful motivation and neurocognition in schizophrenia. Schizophr Res. 193:69–76.
   PubMed Web of Science ®Google Scholar
• Buonocore M, Bosia M, Baraldi MA, Bechi M, Spangaro M, Cocchi F, Bianchi L, Guglielmino C, Mastromatteo AR, Cavallaro R. 2018. Achieving recovery in patients with schizophrenia through psychosocial interventions: a retrospective study. Psychiatry Clin Neurosci. 72(1):28–34.
   PubMed Web of Science ®Google Scholar
• Caldiroli A, Buoli M, Caletti E, Paoli RA, Zago S, Altamura AC. 2013. P.4.009 Age at onset and cognitive impairment in schizophrenia: an ecological cross-sectional study with stabilised patients. Eur Neuropsychopharmacol. 23:S74–S75.
   Web of Science ®Google Scholar
• Capatina OO, Miclutia IV, Toma A. 2017. Relationship between cognition and primary negative symptoms sub-domains in schizophrenia. Eur Psychiatr. 41(S1):S188.
   Google Scholar
• Cuesta MJ, Peralta V. 1995. Psychopathological dimensions in schizophrenia. Schizophr Bull. 21(3):473–482.
   PubMed Web of Science ®Google Scholar
• Daban C, Amado I, Baylé F, Gut A, Willard D, Bourdel M-C, Loo H, Olié J-P, Millet B, Krebs M-O, et al. 2002. Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. Psychiatry Res. 113(1–2):83–92.
   PubMed Web of Science ®Google Scholar
• DeRosse P, Nitzburg GC, Blair M, Malhotra AK. 2018. Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res. 195:385–390.
   PubMed Web of Science ®Google Scholar
• Dibben CRM, Rice C, Laws K, McKenna PJ. 2009. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol Med. 39(3):381–392.
   PubMed Web of Science ®Google Scholar
• Dominguez MdG, Viechtbauer W, Simons CJP, van Os J, Krabbendam L. 2009. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull. 135(1):157–171.
   PubMed Web of Science ®Google Scholar
• Dorofeikova M, Neznanov N, Petrova N. 2018. Cognitive deficit in patients with paranoid schizophrenia: its clinical and laboratory correlates. Psychiatry Res. 262:542–548.
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea E, Vertes PE, Flint SM, Turner L, Mustafa S, Hatton A, Smith KGC, Lyons PA, Bullmore ET. 2016. Peripheral immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. PLoS One. 11(5):e0155631.
   PubMed Web of Science ®Google Scholar
• Fioravanti M, Bianchi V, Cinti ME. 2012. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 12(1):64–64.
   PubMed Web of Science ®Google Scholar
• Han M, Huang X-F, Chen DC, Xiu MH, Hui L, Liu H, Kosten TR, Zhang XY. 2012. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 39(2):358–363.
   PubMed Web of Science ®Google Scholar
• Harvey PD. 2009. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 19(3):324–335.
   PubMed Web of Science ®Google Scholar
• Huang M, Huang Y, Yu L, Hu J, Chen J, Jin P, Xu W, Wei N, Hu S, Qi H, et al. 2016. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry. 16(1):344–310.
   PubMedGoogle Scholar
• Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, Jones PB, Isohanni M, Koponen H, Miettunen J, et al. 2014. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study . Schizophr Res. 158(1–3):134–141.
   PubMed Web of Science ®Google Scholar
• Jagannath V, Theodoridou A, Gerstenberg M, Franscini M, Heekeren K, Correll CU, Rossler W, Grunblatt E, Walitza S. 2017. Prediction analysis for transition to schizophrenia in individuals at clinical high risk for psychosis: the relationship of DAO, DAOA, and NRG1 variants with negative symptoms and cognitive deficits. Front Psychiatry. 8:292.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kochunov P, Coyle TR, Rowland LM, Jahanshad N, Thompson PM, Kelly S, Du X, Sampath H, Bruce H, Chiappelli J, et al. 2017. Association of white matter with core cognitive deficits in patients with schizophrenia. JAMA Psychiatry. 74(9):958–966.
   PubMed Web of Science ®Google Scholar
• Leanza L, Egloff L, Studerus E, Andreou C, Heitz U, Ittig S, Beck K, Uttinger M, Riecher-Rössler A. 2018. The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis. Psychiatry Res. 268:21–27.
   PubMed Web of Science ®Google Scholar
• Li Z, Liu L, Lin W, Zhou Y, Zhang G, Du X, Li Y, Tang W, Zhang X. 2019. NRG3 contributes to cognitive deficits in chronic patients with schizophrenia. Schizophr Res. 215:134–139.
   PubMed Web of Science ®Google Scholar
• Li D, Li X, Yu F, Chen X, Zhang L, Li D, Wei Q, Zhang Q, Zhu C, Wang K. 2017. Comparing the ability of cognitive and affective Theory of Mind in adolescent onset schizophrenia. Neuropsychiatr Dis Treat. 13:937–945.
   PubMed Web of Science ®Google Scholar
• Lim J, Lee SA, Lam M, Rapisarda A, Kraus M, Keefe RSE, Lee J. 2016. The relationship between negative symptom subdomains and cognition. Psychol Med. 46(10):2169–2177.
   PubMed Web of Science ®Google Scholar
• Loewenstein DAPD, Czaja SJPD, Bowie CRPD, Harvey PDPD. 2012. Age-associated differences in cognitive performance in older patients with schizophrenia: a comparison with healthy older adults. Am J Geriatr Psychiatry. 20(1):29–40.
   PubMed Web of Science ®Google Scholar
• Man L, Lv X, Du XD, Yin G, Zhu X, Zhang Y, Soares JC, Yang XN, Chen X, Zhang XY. 2018. Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Res. 263:1–6.
   PubMed Web of Science ®Google Scholar
• Marco JH, Alonso S. 2019. Meaning in life buffers the association between clinical anxiety and global maladjustment in participants with common mental disorders on sick leave. Psychiatry Res. 271:548–553.
   PubMed Web of Science ®Google Scholar
• Mihaljevic-Peles A, Bajs Janovic M, Sagud M, Zivkovic M, Janovic S, Jevtovic S. 2019. Cognitive deficit in schizophrenia: an overview. Psychiatr Danub. 31(2):139–142.
   PubMedGoogle Scholar
• Millan MJ, Fone K, Steckler T, Horan WP. 2014. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 24(5):645–692.
   PubMed Web of Science ®Google Scholar
• Mosiołek A, Gierus J, Koweszko T, Szulc A. 2016. Cognitive impairment in schizophrenia across age groups: a case-control study. BMC Psychiatry. 16(1):37.
   PubMedGoogle Scholar
• Nestor PG, Choate V, Niznikiewicz M, Levitt JJ, Shenton ME, McCarley RW. 2014. Neuropsychology of reward learning and negative symptoms in schizophrenia. Schizophr Res. 159(2–3):506–508.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Ventura J, Subotnik KL, Bartzokis G. 2014. The early longitudinal course of cognitive deficits in schizophrenia. J Clin Psychiatry. 75(2):25–29.
   PubMedGoogle Scholar
• Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. 2012. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 137(1–3):147–150.
   PubMed Web of Science ®Google Scholar
• Rajji TK, Ismail Z, Mulsant BH. 2009. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 195(4):286–293.
   PubMed Web of Science ®Google Scholar
• Randolph C, Tierney MC, Mohr E, Chase TN. 1998. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 20(3):310–319.
   PubMed Web of Science ®Google Scholar
• Schulz SC, Murray A. 2016. Assessing cognitive impairment in patients with schizophrenia. J Clin Psychiatry. 77(2):3–7.
   PubMedGoogle Scholar
• Teigset CM, Mohn C, Brunborg C, Juuhl‐Langseth M, Holmén A, Rund BR. 2018. Do clinical characteristics predict the cognitive course in early-onset schizophrenia-spectrum disorders? J Child Psychol Psychiatry. 59(9):1012–1023.
   PubMed Web of Science ®Google Scholar
• Tomotake M. 2011. Quality of life and its predictors in people with schizophrenia. J Med Invest. 58(3–4):167–174.
   PubMedGoogle Scholar
• Ventura J, Thames AD, Wood RC, Guzik LH, Hellemann GS. 2010. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophrenia Research. 121(1–3):1–14.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Xiu MH, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR. 2012. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One. 7(5):e36563.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR. 2012. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 73(07):1025–1033.
   PubMed Web of Science ®Google Scholar
• Zhang B, Han M, Tan S, De Yang F, Tan Y, Jiang S, Zhang X, Huang X-F. 2017. Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. Sci Rep. 7(1):11821–11828.
   PubMedGoogle Scholar
• Zhang XY, Liang J, Chen DC, Xiu MH, De Yang F, Kosten TA, Kosten TR. 2012. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology. 222(2):277–284.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang M, Du X, Liao W, Chen D, Fan F, Xiu M, Jia Q, Ning Y, Huang X, et al. 2020. Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Mol Psychiatry. 25(12):3220–3230.
   PubMed Web of Science ®Google Scholar
• Zipursky RB. 2014. Why are the outcomes in patients with schizophrenia so poor? J Clin Psychiatry. 75(2):20–24.
   PubMedGoogle Scholar